Corrigendum to “Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19” [Pharmacol. Res. 164 (2021) 105402]

Detalles Bibliográficos
Autores principales: Di Maria, Emilio, Martini, Paolo, Gennarelli, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025071/
https://www.ncbi.nlm.nih.gov/pubmed/33838999
http://dx.doi.org/10.1016/j.phrs.2021.105597

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025071/
https://www.ncbi.nlm.nih.gov/pubmed/33838999
http://dx.doi.org/10.1016/j.phrs.2021.105597

Ejemplares similares